This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Oct;11(10):912-3.

doi: 10.1016/S1470-2045(10)70226-6. Epub 2010 Sep 17.

Kinase inhibitors for refractory thyroid cancers

Martin Schlumberger

PMID: 20851683
DOI: 10.1016/S1470-2045(10)70226-6

Comment

Kinase inhibitors for refractory thyroid cancers

Martin Schlumberger. Lancet Oncol. 2010 Oct.

. 2010 Oct;11(10):912-3.

doi: 10.1016/S1470-2045(10)70226-6. Epub 2010 Sep 17.

Author

Martin Schlumberger

PMID: 20851683
DOI: 10.1016/S1470-2045(10)70226-6

No abstract available

PubMed Disclaimer

Comment on

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Bible KC, et al. Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17. Lancet Oncol. 2010. PMID: 20851682 Free PMC article. Clinical Trial.

Similar articles

Pazopanib for advanced liposarcoma.
Gilbert JA. Gilbert JA. Lancet Oncol. 2017 Oct;18(10):e564. doi: 10.1016/S1470-2045(17)30663-0. Epub 2017 Aug 24. Lancet Oncol. 2017. PMID: 28844815 No abstract available.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Bible KC, et al. Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17. Lancet Oncol. 2010. PMID: 20851682 Free PMC article. Clinical Trial.
Lenvatinib improves survival in refractory thyroid cancer.
Mayor S. Mayor S. Lancet Oncol. 2015 Mar;16(3):e110. doi: 10.1016/S1470-2045(15)70066-5. Epub 2015 Feb 13. Lancet Oncol. 2015. PMID: 25683848 No abstract available.
Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M. Chougnet C, et al. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):448-55. doi: 10.1016/j.clon.2010.04.008. Clin Oncol (R Coll Radiol). 2010. PMID: 20554167 Review.
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Dang RP, McFarland D, Le VH, Camille N, Miles BA, Teng MS, Genden EM, Misiukiewicz KJ. Dang RP, et al. Int J Surg Oncol. 2016;2016:3743420. doi: 10.1155/2016/3743420. Epub 2016 Sep 22. Int J Surg Oncol. 2016. PMID: 27747102 Free PMC article. Review.

See all similar articles

Cited by

The Use of Sorafenib in the Thyroid Cancer.
Zygulska AL, Krzemieniecki K, Sowa-Staszczak A. Zygulska AL, et al. Eur Endocrinol. 2013 Mar;9(1):28-31. doi: 10.17925/EE.2013.09.01.28. Epub 2013 Mar 15. Eur Endocrinol. 2013. PMID: 30349607 Free PMC article. Review.
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N, Houten R, Bagust A, Richardson M, Beale S, Boland A, Dundar Y, Greenhalgh J, Hounsome J, Duarte R, Shenoy A. Fleeman N, et al. Health Technol Assess. 2020 Jan;24(2):1-180. doi: 10.3310/hta24020. Health Technol Assess. 2020. PMID: 31931920 Free PMC article.
New targeted therapies for thyroid cancer.
Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P. Antonelli A, et al. Curr Genomics. 2011 Dec;12(8):626-31. doi: 10.2174/138920211798120808. Curr Genomics. 2011. PMID: 22654562 Free PMC article.
RET TKI: potential role in thyroid cancers.
Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C. Antonelli A, et al. Curr Oncol Rep. 2012 Apr;14(2):97-104. doi: 10.1007/s11912-012-0217-0. Curr Oncol Rep. 2012. PMID: 22286373 Review.
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Jin N, et al. Clin Cancer Res. 2011 Oct 15;17(20):6482-9. doi: 10.1158/1078-0432.CCR-11-0933. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831957 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information